Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase

Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including Toxoplasma gondii. We generated auranofin resistant T. gondii lines throug...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Christopher I., Tirtorahardjo, James A., Jan, Sharon, Schweizer, Sakura S., Rosario, Shawn A. C., Du, Yanmiao, Zhang, Jerry J., Morrissette, Naomi S., Andrade, Rosa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017268/
https://www.ncbi.nlm.nih.gov/pubmed/33816332
http://dx.doi.org/10.3389/fcimb.2021.618994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017268/
https://www.ncbi.nlm.nih.gov/pubmed/33816332
http://dx.doi.org/10.3389/fcimb.2021.618994

Ejemplares similares